X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
QN-01 is a potential breakthrough inhalation small molecule drug therapy, which is currently being investigated for the treatment of smoking cessation.
Lead Product(s): QN-01
Therapeutic Area: Psychiatry/Psychology Product Name: QN-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
The collaboration aims to advance novel inhaled-drug candidates, including QN-05 for the treatment of pneumonia and QN-06 for the treatment of pulmonary infection for individuals exposed to the biodefense agent B. anthracis, the causative agent of anthrax.
Lead Product(s): QN-05
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: QN-05
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: University of Virginia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 19, 2023
Details:
Gaining MHRA approval would validate the safety and efficacy of QN-01. The company believes it is well-positioned to expand the reach and impact of its NRT therapeutic development efforts by pursuing regulatory approval and gaining license as smoking cessation medicine in UK.
Lead Product(s): QN-01
Therapeutic Area: Psychiatry/Psychology Product Name: QN-01
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2022
Details:
The Series A proceeds will be used by Qnovia to advance its NRT drug candidate RespiRx (drud device combination having nicotine) through an IND submission with the FDA and begin human clinical trials in 2023.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: RespiRx
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blue Ledge Capital
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
